The University of Oxford said it has paused administering doses of the Covid-19 vaccine it developed with AstraZeneca PLC in a small U.K. study to test the shot in children and teenagers, pending further information about rare blood-clotting issues in adults who have received it.
The Oxford-led pediatric trial started in mid-February and is aimed at testing the vaccine in more than 200 young people aged 6 to 17 years. An Oxford spokesman said Tuesday that no safety issues have arisen in the trial itself, but broader concerns about rare clotting problems in adults have triggered further regulatory reviews in the U.K. and Europe to investigate any potential link with the vaccine.
Oxford is waiting for more information from the U.K.’s drugs watchdog, the Medicines and Healthcare products Regulatory Agency, before giving any further vaccinations to children or teenagers in the pediatric trial, the spokesman said.
The pause is the latest setback for the Oxford-AstraZeneca shot, which has faced questions about its efficacy and potential side effects even as tens of millions of doses have been administered following safety signoffs in more than 70 countries.
Author(s): Jenny Strasburg, Eric Sylvers
Publication Date: 6 April 2021
Publication Site: Wall Street Journal